美國居民不適用 XM 服務。

Tate & Lyle bulks up food ingredients with $1.8 bln CP Kelco deal



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 3-Tate & Lyle bulks up food ingredients with $1.8 bln CP Kelco deal</title></head><body>

Tate to pay $1.15 bln in cash, rest in shares

J.M. Huber to hold 16% stake in Tate

Tate shares down more than 8%

Updates shares in paragraphs 2 and 8, adds analyst comment in paragraphs 3 and 5

By Radhika Anilkumar

June 20 (Reuters) -Britain's Tate & Lyle TATE.L has struck a $1.8 billion deal to buy U.S.-based CP Kelco to boost its speciality ingredients business and tap demand for plant-based products.

Shares dropped more than 8% after Thursday's announcement, hit by investor concern over CP Kelco performance.

"The deal looks a good fit in terms of scope and size, with a reasonable valuation multiple, although the market will want reassurance that the recent volume decline and margin pressure at CP Kelco reflects cyclical not structural factors," Barclays analysts said in a note.

Sweetener maker Tate & Lyle, which has a market capitalisation of 2.7 billion pounds ($3.4 billion) said it would pay $1.15 billion in cash and issue 75 million new Tate & Lyle shares to CP Kelco's parent company J.M. Huber Corporation.

Barclays noted that CP Kelco's profit margin has dropped about 500 basis points to 17% since 2021, making current profitability lower than its long-term average.

CP Kelco, formed in 2000 by the merger of Kelco and Copenhagen Pectin, provides pectin, speciality gums and other nature-based ingredients such as lily pads, orange peel and seaweed. It was bought by J.M. Huber in 2004.

Tate CEO Nick Hampton said the deal would help the company to meet growing consumer demand for plant-based products with sustainable ingredients and fewer artificial additives.

The company's shares, which fell as much as 8.6% by 1140 GMT, were on track for their biggest one-day fall since March 2020 and were among the biggest fallers on the pan-European STOXX 600 .STOXX index.

The proposed transaction is expected to generate cost benefits of at least $50 million by the end of the second financial year after the deal is completed, Tate added.

The deal is expected to close in the fourth quarter of 2024.

Huber will also become Tate's largest shareholder after the deal, with a stake of about 16%, and will be able to appoint two non-executive directors to the Tate board.


($1 = 0.7870 pounds)



Reporting by Radhika Anilkumar in Bengaluru
Editing by Mrigank Dhaniwala, Mark Potter and David Goodman

</body></html>

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明